<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002489</url>
  </required_header>
  <id_info>
    <org_study_id>91-119</org_study_id>
    <secondary_id>CDR0000077384</secondary_id>
    <secondary_id>NCI-V92-0021</secondary_id>
    <nct_id>NCT00002489</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors</brief_title>
  <official_title>PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      children who have non-testicular malignant germ cell tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of cyclophosphamide, carboplatin, and etoposide in&#xD;
      patients with non-testicular malignant germ cell tumors. II. Improve the quality of life of&#xD;
      these patients by shortening the length of treatment and the extent of initial surgical&#xD;
      resection. III. Determine whether histologic subtypes have prognostic significance. IV.&#xD;
      Determine the efficacy of short term chemotherapy in this patient population. V. Determine&#xD;
      the role of second look surgery in predicting curability of non testicular germ cell tumors.&#xD;
      VI. Determine the role of dose intensification of cyclophosphamide and the introduction of&#xD;
      doxorubicin, methotrexate, and dactinomycin for those patients with partial response, no&#xD;
      response, or progressive disease at the time of second look surgery.&#xD;
&#xD;
      OUTLINE: Patients undergo treatment on Regimen A consisting of surgical resection of tumor as&#xD;
      appropriate for disease followed by chemotherapy with cyclophosphamide IV over 20 minutes on&#xD;
      day 1, carboplatin IV on day 2, and etoposide IV on days 2-4. Patients receive filgrastim&#xD;
      (G-CSF) subcutaneously (SQ) daily beginning 24-48 hours following the last dose of etoposide&#xD;
      and continuing for 14 days or until blood counts recover (a total of 28 days). Chemotherapy&#xD;
      repeats every 3 weeks for 4 courses in the absence of disease progression. At week 11,&#xD;
      patients undergo second look surgery to evaluate response and resect any residual disease.&#xD;
      Patients with no residual disease receive no further therapy. Patients with good partial&#xD;
      response or no response receive salvage chemotherapy on Regimen B. Patients receive salvage&#xD;
      chemotherapy on Regimen B consisting of dactinomycin IV on days 1-3, doxorubicin IV and&#xD;
      vincristine IV continuously on days 1-3, and G-CSF SQ daily beginning 24-48 hours following&#xD;
      last dose of vincristine and continuing for 14 days or until blood counts recover. At week 3,&#xD;
      patients receive cyclophosphamide IV on days 1-2, vincristine IV and doxorubicin IV&#xD;
      continuously on days 1-3 and G-CSF as previously given in Regimen B. At week 6, patients&#xD;
      receive methotrexate IV on day 1 and leucovorin calcium orally or IV every 6 hours for 3&#xD;
      days, beginning 16 hours after the completion of methotrexate. At week 8, salvage&#xD;
      chemotherapy repeats for an additional course. Patients achieving complete response following&#xD;
      salvage chemotherapy receive no further therapy. Patients with no response are removed from&#xD;
      study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 25 patients will be accrued for this study over 6 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1991</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dactinomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Malignant germ cell tumors of the following stages and primary&#xD;
        sites: Stage II/III/IV ovarian tumors Grade II/III immature glial teratomas Stage II/III/IV&#xD;
        mediastinal tumors Stage II/III/IV presacral tumors and tumors of other primary sites No&#xD;
        intracranial or testicular primary sites&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Child Performance status: Not specified Hematopoietic: Not&#xD;
        specified Hepatic: Not specified Renal: Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norma Wollner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2004</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage II ovarian germ cell tumor</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>ovarian teratoma</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

